Update shared on 07 Nov 2025
Fair value Decreased 0.68%Becton Dickinson Analyst Price Target Narrative Update
The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term.
Analyst Commentary
Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities. Commentary focuses on factors tied to valuation, strategic execution, and growth outlook.
Bullish Takeaways- Bullish analysts see potential for a new phase of growth following the planned business separation slated for early 2026. They expect this move to streamline operations and focus the company's strategy.
- The current fair value and price targets indicate some confidence that foundational strengths and improved positioning could result in meaningful gains once near-term challenges abate.
- Analysts emphasize that Becton Dickinson’s stable market presence in medical technology supports a solid base for future expansion.
- Bearish analysts highlight a conservative fiscal 2026 outlook, forecasting limited earnings growth until at least 2027. This tempers near-term valuation excitement.
- There are concerns that more attractive investment opportunities exist elsewhere in the medtech sector, prompting a neutral view on the stock’s potential for outperformance.
- Uncertainty related to the effectiveness and execution of the upcoming business separation introduces additional risk regarding the timeline and magnitude of expected benefits.
What's in the News
- BD's Board of Directors approved a quarterly dividend increase to $1.05 per share, raising the annual rate to $4.20 for fiscal 2026. (Company Announcement)
- BD received FDA clearance and CE marking in the EU for its Enteric Bacterial Panel and Panelplus on the BD COR™ System. This expands diagnostic options for gastrointestinal bacterial pathogens. (Company Announcement)
- The company completed full enrollment of the iliac artery cohort in the pivotal AGILITY IDE study, which assesses the Revello Vascular Covered Stent for patients with peripheral arterial disease. (Company Announcement)
- Becton Dickinson introduced the BD Incada™ Connected Care Platform, an AI-enabled, cloud-based system that unifies device data. The company also launched the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution. (Company Announcement)
- BD announced an executive transition. CFO Chris DelOrefice is set to depart in December 2025 and Vitor Roque has been named interim CFO pending a permanent successor. (Company Announcement)
Valuation Changes
- Fair Value Estimate has declined modestly from $208 to approximately $206.58, reflecting a more cautious earnings outlook.
- Discount Rate has risen slightly from 8.17% to about 8.57%, indicating a higher risk premium now factored into valuations.
- Revenue Growth assumptions have fallen significantly from 4.87% to 2.64%. This suggests more conservative expectations for future top-line expansion.
- Net Profit Margin projection has increased marginally from 11.30% to 11.81%, reflecting anticipated efficiency improvements.
- Future P/E Ratio estimate has risen slightly from 26.36x to 26.45x. This indicates a modest adjustment in forward valuation multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.